Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Memorial Sloan Kettering Cancer Center
Medical University of South Carolina
Janssen Biotech, Inc.
Massachusetts General Hospital
Cedars-Sinai Medical Center
Dana-Farber Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Institut Cancerologie de l'Ouest
Emory University
Johns Hopkins University
University of Utah
Bristol-Myers Squibb
Montefiore Medical Center
Wake Forest University Health Sciences
University of Michigan Rogel Cancer Center
Exelixis
RTOG Foundation, Inc.
Janssen Research & Development, LLC
Bristol-Myers Squibb
Medical University of South Carolina
UNC Lineberger Comprehensive Cancer Center
University of California, San Francisco
University of Wisconsin, Madison
Medical College of Wisconsin
M.D. Anderson Cancer Center
Emory University
National Cancer Institute (NCI)
Progenics Pharmaceuticals, Inc.
National Cancer Institute (NCI)
Duke University
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Brown University
Dana-Farber Cancer Institute
VA Greater Los Angeles Healthcare System
Canadian Cancer Trials Group
University of California, San Francisco
University of Wisconsin, Madison
University of Colorado, Denver
Coherus Oncology, Inc.
Thomas Jefferson University
Thomas Jefferson University
Thomas Jefferson University
Janssen Research & Development, LLC
Elevation Oncology